VP 002 - Vision Pharma

Alternative Names: VP-002 - Vision Pharma

Latest Information Update: 03 Mar 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lions Eye Institute; PYC Therapeutics
Developer Vision Pharma
Class Antisense oligonucleotides; Eye disorder therapies; Morpholines; Peptide drug conjugates
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

14 Feb 2023 Discontinued - Preclinical for Optic atrophy in Australia (Intravitreous) (PYC Therapeutics Pipeline, February 2023)
29 Jun 2021 PYC Therapeutics plans to file an IND application with the US FDA for Optic atrophy in USA, in the first half of 2023
29 Jun 2021 Pharmacodynamics data from a preclinical study in Optic atrophy released by PYC Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com